secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001140361-23-052718
Event type: earnings
Sentiment:  positive
Materiality: 1.00
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant reports Q2 net loss $331M; announces $7.1B Telavant sale to Roche
-------------------------------------------------------------------------

- Net loss $331.1M ($0.40/share) vs $315.9M prior year; revenue $37.1M up from $12.5M.
- Sold Telavant to Roche for $7.1B upfront + $150M milestone; Roivant net proceeds ~$5.2B.
- VTAMA net product revenue $18.4M in quarter; over 250k prescriptions since launch.
- Pro forma cash ~$7.0B after Telavant and Immunovant offerings; R&D spend $132M.
- IMVT-1402 Phase 1 data show dose-dependent IgG reduction with no significant albumin/LDL-C changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123052718/0001140361-23-052718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123052718/ef20014462_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-052718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer